Source link : https://www.newshealth.biz/health-news/no-dfs-benefit-with-adjuvant-durvalumab-in-early-nsclc/
Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small cell lung cancer (NSCLC), according to findings from the phase 3 BR.31 trial. In the overall population, median disease-free survival (DFS) was about 6 months longer in the durvalumab arm, but the difference was not […]
Author : News Health
Publish date : 2024-09-14 18:01:14
Copyright for syndicated content belongs to the linked Source.
Categories